City

Bogota (1)

Chongqing (1)

Condition

EGFR G719X (2)

EGF-R Positive Non-Small Cell Lung Cancer (1)

EGFR Exon 19 Deletion (1)

EGFR Exon 21 Mutation (1)

EGFR L861Q (1)

EGFR S768I (1)

Non Small Cell Lung Cancer (1)

Non-small Cell Lung Cancer (1)

Overall Status

Not yet recruiting (1)

Recruiting (1)

Sign in for free

Phase

n/a (1)

phase 2 (1)

Sponsor

Centro de Tratamiento e Investigacion sobre Cancer, Luis Carlos Sarmiento Angulo (1)

Chongqing University Cancer Hospital (1)

Collaborator

Army Specialty Medical Center (1)

The Second Affilicated Hospital of Chongqing Medical University (1)

Intervention

furmonertinib 160 mg, q.d. (1)

stereotactic body radiation therapy sbrt (1)

Study Documents

Intervention Type

drug (1)

radiation (1)

Funder Type

Other (2)

Study Type

Interventional (2)

egfr g719x

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

EGF-R Positive NSCLC, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion Trial in Bogotá (Stereotactic Body Radiation Therapy

Not yet recruiting

EGF-R Positive Non-Small Cell Lung Cancer
+4 more

Stereotactic Body Radiation Therapy SBRT

Bogotá, Colombia

CTIC - Centro de Tratamiento e Investigación Sobre Cáncer Luis C

Aug 16, 2023

NSCLC, EGFR G719X, EGFR L861Q Trial in Chongqing (Furmonertinib 160 mg, Q.D.)

Recruiting

Non-small Cell Lung Cancer
+3 more

Furmonertinib 160 mg, Q.D.

Chongqing, Chongqing, China
+2 more

Sep 16, 2022